Retinal Vein Occlusion Market Report 2026

The retinal vein occlusion market size has grown strongly in recent years. It will grow from $17.03 billion in 2025 to $18.71 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to increasing prevalence of hypertension and diabetes, growing awareness of retinal vascular diseases, improved availability of diagnostic imaging tools, expansion of ophthalmology departments, rising clinical research activities.

The retinal vein occlusion market size is expected to see rapid growth in the next few years. It will grow to $28.23 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to increasing aging population, rising demand for minimally invasive treatments, expansion of personalized ophthalmic care, growing investments in retinal disease research, increasing adoption of combination therapy approaches. Major trends in the forecast period include increasing adoption of anti-vegf therapies, rising use of advanced retinal imaging diagnostics, growing focus on early detection of vascular disorders, expansion of outpatient ophthalmic treatment models, enhanced monitoring of disease progression.

The growing prevalence of eye disorders is anticipated to drive the growth of the ocular drug delivery market in the coming years. Eye disorders encompass a broad range of conditions that affect the eyes, vision, or the surrounding ocular structures. The rising incidence of retinal vein occlusion contributes to market growth by increasing the demand for advanced diagnostic solutions and effective therapeutic interventions to manage this condition. For example, in October 2023, according to the Royal National Institute of Blind People (RNIB), a UK-based sight loss charity, eye care outpatient appointments in the UK exceeded eight million in 2021/22, the highest among all medical specialties. Additionally, the number of people living with sight loss, currently more than two million, is projected to double to over four million by 2050. Therefore, the increasing prevalence of eye disorders is driving the growth of the retinal vein occlusion market.

Major companies operating in the retinal vein occlusion market are concentrating on the development of innovative technologies, such as next-generation pattern-scanning laser platforms, to improve treatment accuracy, procedural efficiency, and personalized disease management. Next-generation pattern-scanning laser platforms are advanced ophthalmic laser systems that combine high-speed pattern delivery, tissue-sparing energy control, and multimodal laser functionalities to enhance therapeutic outcomes for retinal vascular conditions. For instance, in April 2023, Iridex Corporation, a US-based ophthalmic medical technology company, launched the next-generation Iridex PASCAL platform. This advanced system integrates rapid and precise pattern-scanning capabilities, endpoint management technology, pattern-scanning laser trabeculoplasty, and micropulse technology into a compact and ergonomically designed integrated laser platform, enabling more individualized treatment for patients with retinal diseases.

In October 2025, Novartis Pharma Services AG, a Switzerland-based pharmaceutical research, development, and manufacturing company, entered into an exclusive five-year distribution agreement with CMS Vision International Management Ltd. for two ophthalmic drugs. This agreement aims to leverage Kangzhi’s established presence and extensive sales network in ophthalmology to expand product access and commercial reach across China. Novartis Pharma Services AG develops and supplies innovative pharmaceutical products, while CMS Vision International Management Ltd. (Kangzhi) is a China-based company specializing in ophthalmic drugs and devices for conditions including retinal diseases, glaucoma, and ocular fatigue.

Major companies operating in the retinal vein occlusion market are Pfizer Inc., Roche Holding AG, Merck And Co Inc., Bayer AG, Novartis AG, Allergan PLC, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Carl Zeiss AG, Santen Pharmaceutical Co Ltd, Lumenis Ltd, Coherus Biosciences Inc., Genentech Inc., Topcon Corporation, Nidek Co Ltd, IRIDEX Corporation, Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Ellex Medical Lasers Ltd, Adverum Biotechnologies Inc., Outlook Therapeutics Inc., Annexin Pharmaceuticals AB, Ingenia Therapeutics Inc., Samsung Bioepis.

North America was the largest region in the retinal vein occlusion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the retinal vein occlusion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the retinal vein occlusion market by increasing costs of imported diagnostic imaging systems, injectable therapeutics, laser equipment, and ophthalmic consumables used in disease diagnosis and management. Healthcare providers in North America and Europe are most affected due to reliance on imported retinal imaging and treatment technologies, while Asia-Pacific faces higher procurement costs for advanced devices. These tariffs are increasing treatment costs and impacting patient access. At the same time, they are encouraging local production of ophthalmic equipment, regional drug manufacturing, and broader adoption of cost-optimized treatment pathways.

The retinal vein occlusion market research report is one of a series of new reports that provides retinal vein occlusion market statistics, including retinal vein occlusion industry global market size, regional shares, competitors with a retinal vein occlusion market share, detailed retinal vein occlusion market segments, market trends and opportunities, and any further data you may need to thrive in the retinal vein occlusion industry. This retinal vein occlusion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Retinal vein occlusion (RVO) is a medical condition that occurs when there is a blockage or obstruction in the veins responsible for carrying blood away from the retina, the light-sensitive tissue at the back of the eye. RVO can be prevented by managing other blood vessel-related conditions that increase the risk of its development, which can be achieved through a low-fat diet, regular physical activity, and maintaining a healthy body weight.

The main types of retinal vein occlusion include branch retinal vein occlusion and central retinal vein occlusion. Branch retinal vein occlusion refers to a condition in which blood flow is reduced in a branch of the central retinal vein, leading to ischemic damage in the affected region of the retina, and it may be treated with ocular hypotensive drugs such as topical timolol or intravenous or oral acetazolamide. These conditions are classified into non-ischemic and ischemic forms and are diagnosed using optical coherence tomography, fundoscopic examination, and fluorescein angiography. Treatment approaches include anti-vascular endothelial growth factor therapies, corticosteroid medications, and laser retinal photocoagulation, and are provided by end users such as hospitals and clinics, research and academic centers, and others.

The retinal vein occlusion market consists of revenues earned by entities by providing services such as surgery and pan retinal photocoagulation. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinal vein occlusion market also includes sales of ranibizumab and aflibercept. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.